Stress granules—membraneless organelles as therapeutic targets in pancreatic cancer
Therapies targeting pancreatic ductal adenocarcinoma (PDAC), driven in most cases by the KRAS oncogene, continue to present a clinical challenge. This emphasizes the need to explore alternative treatment paradigms in translational research. In this issue of EMBO Mol. Med. , Santofimia-Castano et al, highlight that stress-inducible nuclear protein 1 (NUPR1), an intrinsically disordered protein, serves as a regulator of KRAS-associated stress granules (SGs) (Santofimia-Castaño et al, 2024 ). Targeting NUPR1 by a small molecule inhibitor prevents SG formation as well as the development and progression of pancreatic intraepithelial neoplasia (PanINs). Moreover, the NUPR1 inhibitor ZW-115 triggers apoptosis of PDAC cells dependent on KRAS expression. In essence, these findings are supportive of targeting SGs as a therapeutic approach for PDAC (Santofimia-Castaño et al, 2024 ).
G. Schneider & C. Schneider discuss the study by Santofimia-Castaño et al, in this issue of EMBO Mol. Med. , that shows that targeting NUPR1-dependent stress granules formation induces synthetic lethality in a mouse model of pancreatic cancer.
Preview
Cite
Access Statistic




